Evidence map›Paper›PMID 37917812›Full record

ArticleThe Journal of international medical research2023

Advanced renal pelvis carcinoma patient with an ERBB2 insertion mutation: a case report.

Peipei Shang, Cheng Lou, Lei Yin, Chenjie Tao, Yulong Dong, Guang Yang, Zhengang Yuan

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 67% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Peipei ShangDepartment of Oncology, Shanghai Eastern Hepatobiliary Surgery Hospital, Anting Town, Jiading District, Shanghai, China.
Cheng LouDepartment of Oncology, Shanghai Eastern Hepatobiliary Surgery Hospital, Anting Town, Jiading District, Shanghai, China.
Lei YinDepartment of Oncology, Shanghai Eastern Hepatobiliary Surgery Hospital, Anting Town, Jiading District, Shanghai, China.
Chenjie TaoDepartment of Oncology, Shanghai Eastern Hepatobiliary Surgery Hospital, Anting Town, Jiading District, Shanghai, China.
Yulong DongDepartment of Oncology, Shanghai Eastern Hepatobiliary Surgery Hospital, Anting Town, Jiading District, Shanghai, China.
Guang YangDepartment of Oncology, Shanghai Eastern Hepatobiliary Surgery Hospital, Anting Town, Jiading District, Shanghai, China.
Zhengang YuanDepartment of Oncology, Shanghai Eastern Hepatobiliary Surgery Hospital, Anting Town, Jiading District, Shanghai, China.ORCID 0000-0002-0584-4072
Second Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of renal pelvis cancer is poor and therapeutic options are limited, especially for patients with advanced disease. In this report, we present a case of advanced renal pelvis carcinoma in a male patient in his 60s, characterized by an activating mutation in

Indexed as

Kidney NeoplasmsPelvic NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansKidney PelvisMaleMutagenesis, InsertionalMutationNeoplasm Recurrence, LocalTrastuzumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabcase reportdrug resistanceERBB2 mutationmetastasisrecurrencerenal pelvis cancer

Identifiers

PMID37917812
PMCPMC10623987
OpenAlexW4388213069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.